Skip to main content

Advertisement

Log in

Malignancy in scleroderma patients from south west England: a population-based cohort study

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The pathophysiological relationship between scleroderma and malignancy remains poorly understood. Although some previous studies have demonstrated an increased malignancy risk in patients with scleroderma, others have been inconclusive. We aimed to determine if patients with scleroderma had an increased risk of malignancy compared to an age- and sex-matched local South West England population, and if there were any important differences between scleroderma patients with and without malignancy. Methods of this study are as follows. Notes were obtained on all local scleroderma patients (n = 68) locally, and those diagnosed with malignancy verified by contacting each patient’s general practitioner. Expected malignancy figures were obtained from age- and sex-stratified regional prevalence data provided by the South West Cancer Intelligence Service registry. Among the patients, 22.1% with scleroderma were identified with concurrent malignancy. Affected sites were of the breast (n = 5), haematological system (n = 5), skin (n = 4), and unknown primary (n = 1). Overall, malignancy risk was found to be increased in scleroderma (RR = 3.15, 95% CI 1.77–5.20, p = 0.01). In particular, this risk was the highest for haematological malignancies (RR = 18.5, 95% CI 6–43, p = 0.03), especially for non-Hodgkin’s lymphoma (RR = 25.8, 95% CI 5–75, p = 0.10). The majority of patients (86.7%) developed malignancy after the onset of scleroderma (mean = 6.9 years). Age of >70 and patients with limited scleroderma were significant risk factors for a patient with scleroderma to have a concurrent malignancy; however, no increased risk was found in patients with any particular pattern of organ involvement, cytotoxic usage or serology. To conclude, in this small patient cohort, we have found that scleroderma is associated with an increased risk of malignancy. This risk is statistically significant in patients with limited scleroderma. Patients who are elderly and those with limited disease should be closely scrutinized at follow-up appointments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sigurgeirsson B, Lindelöf B, Edhag O et al (1992) Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 326:363–367

    Article  PubMed  CAS  Google Scholar 

  2. Lazarus MN, Robinson D, Mak V et al (2006) Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 45(8):1012–1015

    Article  PubMed  CAS  Google Scholar 

  3. Gayed M, Bernatsky S, Ramsey-Goldman R et al (2009) Lupus and cancer. Lupus 18(6):479–485

    Article  PubMed  CAS  Google Scholar 

  4. Smitten AL, Simon TA, Hochberg MC et al (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45. doi:10.1186/ar2404

    Article  PubMed  Google Scholar 

  5. Zatuchni J, Campbell WN, Zarafonetis CJ (1953) Pulmonary fibrosis and terminal bronchiolar (alveolar-cell) carcinoma in scleroderma. Cancer 6(6):1147–1158

    Article  PubMed  CAS  Google Scholar 

  6. Pearson JE, Silman AJ (2003) Risk of cancer in patients with scleroderma. Ann Rheum Dis 62:697–699

    Article  PubMed  CAS  Google Scholar 

  7. Rosenthal AK, McLaughlin JK, Gridley G et al (1995) Incidence of cancer among patients with systemic sclerosis. Cancer 76:910–914

    Article  PubMed  CAS  Google Scholar 

  8. Hill CL, Nguyen AM, Roder D et al (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62(8):728–731

    Article  PubMed  CAS  Google Scholar 

  9. Chatterjee S, Dombi GW, Severson RK et al (2005) Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 52(8):2415–2424

    Article  PubMed  Google Scholar 

  10. Duncan SC, Winkelmann RK (1979) Cancer and scleroderma. Arch Dermatol 115:950–955

    Article  PubMed  CAS  Google Scholar 

  11. LeRoy EC, Black C, Fleischmajer R (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  12. Uitenbroek, Daan G (1997) Binomial. SISA. http://www.quantitativeskills.com/sisa/distributions/binomial.htm. (1 Jan. 2004)

  13. Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 37:750–755

    Article  PubMed  CAS  Google Scholar 

  14. Grady WM (2005) Transforming growth factor-β, Smads and cancer. Clin Cancer Res 11:3151–3154

    Article  PubMed  CAS  Google Scholar 

  15. Dong M, Blobe GC (2006) Role of transforming growth factor-beta in haematologic malignancies. Blood 107(12):4589–4596

    Article  PubMed  CAS  Google Scholar 

  16. Kretzschmar M (2000) Transforming growth factor-β and breast cancer: transforming growth factor-β/SMAD signaling defects and cancer. Breast Cancer Res 2(2):107–115

    Article  PubMed  CAS  Google Scholar 

  17. Radis CD et al (1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 38:1120–1127

    Article  PubMed  CAS  Google Scholar 

  18. Abu-Shakra M et al (2001) Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 60:433–441

    Article  PubMed  CAS  Google Scholar 

  19. Wenzel J (2002) Scleroderma and malignancy: mechanisms of interrelationship. Eur J Dermatol 12(3):296–300

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Keith Siau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siau, K., Laversuch, C.J., Creamer, P. et al. Malignancy in scleroderma patients from south west England: a population-based cohort study. Rheumatol Int 31, 641–645 (2011). https://doi.org/10.1007/s00296-009-1348-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1348-y

Keywords

Navigation